Stay updated on Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial

Sign up to get notified when there's something new on the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The clinical trial record for a Phase 2 study of Telomelysin (OBP-301) with pembrolizumab in esophagogastric adenocarcinoma is displayed, with study design, participant criteria, outcome measures, locations, and record history.
    Difference
    49%
    Check dated 2026-11-11T02:22:09.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-04T01:18:46.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    A general NIH notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the blocked study page. The site revision label also changes from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-21T01:12:19.000Z thumbnail image
  5. Check
    37 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision identifier changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-07T01:13:55.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error, replacing the full study record with a minimal header and Home link, and the previously visible trial details are no longer accessible on this page.
    Difference
    18%
    Check dated 2026-09-23T01:29:48.000Z thumbnail image
  7. Check
    58 days ago
    Change Detected
    Summary
    Revision tag on the page updated to v3.7.0, replacing the previous v3.6.6. This indicates a minor update to the page's metadata or underlying CMS without changing the visible study content.
    Difference
    0.1%
    Check dated 2026-09-16T00:29:41.000Z thumbnail image

Stay in the know with updates to Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page.